<DOC>
	<DOCNO>NCT00952016</DOCNO>
	<brief_summary>To assess efficacy methotrexate genetically select population patient advance colorectal cancer , loss particular gene , MSH2 . The efficacy methotrexate evaluate proportion case significant response treatment ( objective response rate ) .</brief_summary>
	<brief_title>Methotrexate Metastatic Colorectal Cancer With MSH2 Deficiency</brief_title>
	<detailed_description>The study involve treat 29 subject methotrexate give intravenously . All subject receive treatment ; control arm randomisation . The subject know deficiency MSH2 , mutation ( genetic change ) MSH2 stop function normally . This either demonstrate test loss MSH2 protein tumour , demonstration mutation MSH2 gene subject 's blood .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Confirmed diagnosis metastatic locally recurrent colorectal carcinoma Aged 18 year old Paraffin embed histological material available analysis Either confirm loss expression MSH2 immunohistochemistry IHC confirm mutation MSH2 gene sequence Life expectancy &gt; 3 month Previous treatment methotrexate , either malignant nonmalignant disease , except methotrexate give low dose drug modify effect Concomitant uncontrolled medical condition Concomitant metastatic malignancy apart nonmelanotic skin cancer carcinoma situ uterine cervix last 10 year Any contraindication treatment methotrexate ( affect safety )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>MSH2</keyword>
	<keyword>metastatic</keyword>
</DOC>